Clinical Trial of Sofosbuvir/Ribavirin for HCV Genotype 2-infected Japanese Patients

Clinical Trial of Sofosbuvir/Ribavirin for HCV Genotype 2-infected Japanese Patients - Oral regimen for Genotype 2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018554

Enrollment

Registered

2015-08-05

Start date

2015-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C (genotype 2)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 2 patients Patients who satisfied the indication for sofosbuvir and ribavirin Chronic hepatitis or compensated liver cirrhosis

Exclusion criteria

Exclusion criteria: Patients who have allergy to sofosbuvir or ribavirin Patients with renal dysfunction Patients with less than 12 g/dl hemoglobin Patients expecting a child and have a possibility of pregnancy or who are breast-feeding Patients taking contraindicated drug Patients whom the doctor in attendance judged as inappropriate

Design outcomes

Primary

Measure	Time frame
sustained virological response	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results